|
| Date |
Type |
Disease |
Title |
|
May 12, 2008 |
Abstract |
CFIDS&FM |
S-Adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: A double-blind cross-over trial [ISRCTN36233495] – Source: BMC Musculoskeletal Disorders, Feb 2004
The dietary supplement SAMe has a slower onset of action but supports improved comfort in knee osteoarthritis patients as effectively as the prescription NSAID drug celecoxib (brand name CelebrexR). [Source: BMC Musculoskeletal Disorders, Feb 2004] |
|
May 09, 2008 |
Abstract |
CFIDS&FM |
Curcumin and cancer: An ‘old-age’ disease with an ‘age-old’ solution – Source: Cancer Letters, May 5, 2008
MD Anderson Cancer Center summarizes research indicating the potential benefits of curcumin to support the body’s defenses against various types of cancer (not to mention many other conditions, from arthritis and Alzheimer's to psoriasis). [Source: Cancer Letters, May 5, 2008] |
|
May 09, 2008 |
Abstract |
CFIDS&FM |
Assessment of pain: A community-based diary survey in the USA – Source: The Lancet, May 2008
National survey finds more than one-fourth of U.S. adults suffer daily pain; with some differences by economic status; calculates the national cost in lost productivity. [Source: The Lancet, May 2008] |
|
May 08, 2008 |
Abstract |
CFIDS&FM |
Role of central dopamine in pain and analgesia - Source: Expert Review of Neurotherapeutics, May 2008
Patrick B Wood's scientific update on the role of dopamine abnormalities/activity in central nervous system pain perception & pain relief for FM, Parkinson’s, RLS, etc. Continued research "may lead to the development of novel therapeutic strategies." [Source: Expert Review of Neurotherapeutics, May 2008] |
|
May 08, 2008 |
Abstract |
CFIDS&FM |
The significance of the sleeping-waking brain for the understanding of widespread musculoskeletal pain and fatigue in Fibromyalgia syndrome and allied syndromes – Source: Joint, Bone, Spine, May 2, 2008
Researchers are understanding increasingly that disturbances in the brain's sleep-wake cycle are a significant factor in FM pain & fatigue - along with a focus on medications to address them. [Source: Joint, Bone, Spine, May 2, 2008] |
|
May 07, 2008 |
Abstract |
CFIDS&FM |
Double-blind Placebo-Controlled Trial of Amitriptyline for the Treatment of Irritable Bowel Syndrome in Adolescents – Source: Journal of Pediatrics, May 2008
Though this drug comes with a black box warning for adolescents when used for depression, this small UCLA trial indicates a lower dose (already used in adult IBS treatment) offers promise for improved quality of life in adolescents with IBS. Long-term follow-up and investigation of alternatives is planned. [Source: Journal of Pediatrics, May 2008] |
|
May 07, 2008 |
Article |
CFIDS&FM |
Antidepressant found to alleviate symptoms of Irritable Bowel Syndrome in adolescents
UCLA trial reports small doses of the tricyclic antidepressant amitriptyline (shown to be effective for adults with IBS) significantly improved pain & quality of life for adolescents with IBS. |
|
May 06, 2008 |
Abstract |
CFIDS&FM |
Comorbid Somatic Symptoms and Functional Status in Patients With Fibromyalgia and Chronic Fatigue Syndrome: Sensory Amplification as a Common Mechanism – Source: Psychosomatics, May 2008
In ME/CFS & FM patients, heightened perception of sense-stimulation - including pain - may be an underlying pathophysiologic mechanism, and appears relatively independent of depression and depressive symptoms. [Source: Psychosomatics, May 2008] |
|
May 02, 2008 |
Article |
CFIDS&FM |
International Study of Drug to Control Progression of Osteoarthritis Recruiting Now at 71 Locations
71 centers in 10 countries & Canadian provinces are now recruiting female subjects with knee osteoarthritis, also known as ‘degenerative joint disease,’ for a 2-year Phase II study. Target enrollment is 1,400. |
|
May 01, 2008 |
Abstract |
CFIDS&FM |
Arthritis develops but fails to resolve during inhibition of cyclooxygenase 2 [COX-2] in a murine model of Lyme disease – Source: Arthritis and Rheumatism, Apr 25, 2008
COX-2 is an enzyme responsible for inflammation and pain. COX-2 inhibitor products include non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin or ibuprofen. This study suggests COX-2 inhibitors may also inhibit the ‘signaling molecules’ that resolve inflammation. These eicosanoids are produced by oxygenation of the omega-3 fatty acid EPA, found in fish oil. [Source: Arthritis and Rheumatism, Apr 25, 2008] |
|
|
Next 10 Articles>> |
|
|
|
